Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel in connection with the acquisition of Progrits, a leading software company in vertical software and information services
Mandate

Vinge advises Axcel in connection with the acquisition of Progrits, a leading software company in vertical software and information services

June 14, 2023 M&A EU, Competition and Regulatory Commercial Agreements Employment and Benefits Banking and Finance Intellectual Property IT, Telecommunications and Outsourcing Data protection and processing of personal data

Progrits consists of ten businesses that develop specialised solutions within transport and logistics, vehicle digital solutions and integrated e-commerce. The B2B software company simplifies and automates customer information handling and workflows for approximately 5,000 Nordic and international customers.

The acquisition is subject to approval from applicable competition authority.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson, Nando Basic and Josef Groow (M&A), Mathilda Persson and Alva Skott (Commercial Agreements), August Ahlin (Banking and Financing), Madelene Andersson (Real Estate), Julia Löfqvist (Compliance), Tove Hallbäck (Employment), Lisa Hörnqvist (IT and GDPR), Arvid Axelryd and Felizia Wiker (Intellectual Property), Sebastian Örndahl, Victoria Fredén and Hampus Peterson (Merger filing) and Ellinore Boström Andersson (Project Assistant).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026